44 related articles for article (PubMed ID: 35750276)
1. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
Mutat Res; 2023; 827():111834. PubMed ID: 37531716
[TBL] [Abstract][Full Text] [Related]
2. Circular RNAs in cholangiocarcinoma.
Liao W; Feng Q; Liu H; Du J; Chen X; Zeng Y
Cancer Lett; 2023 Jan; 553():215980. PubMed ID: 36336149
[TBL] [Abstract][Full Text] [Related]
3. Replication stress as a driver of cellular senescence and aging.
Herr LM; Schaffer ED; Fuchs KF; Datta A; Brosh RM
Commun Biol; 2024 May; 7(1):616. PubMed ID: 38777831
[TBL] [Abstract][Full Text] [Related]
4. The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence.
Buchynska L; Gordiienko I; Glushchenko N; Iurchenko N
PLoS One; 2024; 19(4):e0302075. PubMed ID: 38669256
[TBL] [Abstract][Full Text] [Related]
5. Ceramide kinase-mediated C1P metabolism attenuates acute liver injury by inhibiting the interaction between KEAP1 and NRF2.
Dong W; Li Q; Lu X; Lan J; Qiu Z; Wang X; Wang J; Zheng X; Chen S; Zhang C; Jin J
Exp Mol Med; 2024 Apr; 56(4):946-958. PubMed ID: 38556546
[TBL] [Abstract][Full Text] [Related]
6. Targeting E2F Sensitizes Prostate Cancer Cells to Drug-Induced Replication Stress by Promoting Unscheduled CDK1 Activity.
Hamidi M; Eriz A; Mitxelena J; Fernandez-Ares L; Aurrekoetxea I; Aspichueta P; Iglesias-Ara A; Zubiaga AM
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230876
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategies for cancer therapy by ATR inhibitors.
Yano K; Shiotani B
Cancer Sci; 2023 Jul; 114(7):2709-2721. PubMed ID: 37189251
[TBL] [Abstract][Full Text] [Related]
8. DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response.
Lin YF; Shih HY; Shang Z; Matsunaga S; Chen BP
Nucleic Acids Res; 2014 Apr; 42(7):4463-73. PubMed ID: 24500207
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53.
Segeren HA; van Liere EA; Riemers FM; de Bruin A; Westendorp B
Oncogene; 2022 May; 41(19):2719-2733. PubMed ID: 35393546
[TBL] [Abstract][Full Text] [Related]
10. Dormant origin signaling during unperturbed replication.
Moiseeva TN; Bakkenist CJ
DNA Repair (Amst); 2019 Sep; 81():102655. PubMed ID: 31311769
[TBL] [Abstract][Full Text] [Related]
11. An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication.
Moiseeva TN; Yin Y; Calderon MJ; Qian C; Schamus-Haynes S; Sugitani N; Osmanbeyoglu HU; Rothenberg E; Watkins SC; Bakkenist CJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13374-13383. PubMed ID: 31209037
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms used by cancer cells to tolerate drug-induced replication stress.
Segeren HA; Westendorp B
Cancer Lett; 2022 Sep; 544():215804. PubMed ID: 35750276
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
